AVLN compared with MPLT: revenue, margins and what each company keeps, and the suppliers and customers both name

AVLNAvalyn Pharma Inc.

Mkt capRevenueRevenue

MPLTMapLight Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AVLNAvalyn Pharma Inc.

MPLTMapLight Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AVLN1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+5.41%—

MPLT

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±16.4%▲+1.47%×0.09

May 15 '26—▼−1.91%—

= impliedAVLN realized, solidMPLT realized, hatchedOne scale, both sides: full bar = 17%× = |realized| ÷ impliedSource: market data

Q1 FY26

—

▲+6.01%

—

Jan 9 '26—▲+4.83%—

AVLNAvalyn Pharma Inc.

26.62· pre 26.62· delayed

Mkt cap$790.8M

MPLTMapLight Therapeutics, Inc.

6.22· pre 6.33· delayed

Pre-marketNov 5 '26delayed

Mkt cap$282.6M

Compare

Pre-marketNov 5 '26delayed

AVLNAvalyn Pharma Inc.

MPLTMapLight Therapeutics, Inc.

26.62pre 26.62delayed

Price

6.22pre 6.33delayed

$790.8M

Mkt cap

$282.6M

AVLN26.62vsMPLT6.22Pre-marketNov 5 '26delayed